Arora Aakriti, Zaemes Jacob, Ozdemirli Metin, Kim Chul
Department of Medicine, MedStar Washington Hospital Center, Washington, DC, United States.
Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, United States.
Front Oncol. 2023 Mar 14;13:1134151. doi: 10.3389/fonc.2023.1134151. eCollection 2023.
Large-cell neuroendocrine carcinoma (LCNEC) is a rare subtype of non-small-cell lung cancer associated with a poor prognosis. LCNEC is genetically heterogeneous, and studies have revealed distinct molecular subtypes of LCNEC, which may have therapeutic implications. Herein, we present a case of a patient with stage IV LCNEC harboring a - fusion whose disease responded to the selective RET inhibitor selpercatinib both extra- and intra-cranially, highlighting the importance of comprehensive molecular testing in LCNEC for selection of optimal treatment.
大细胞神经内分泌癌（LCNEC）是一种罕见的非小细胞肺癌亚型，预后较差。LCNEC具有基因异质性，研究已揭示出LCNEC不同的分子亚型，这可能具有治疗意义。在此，我们报告一例IV期LCNEC患者，其携带一种-融合基因，该患者的疾病在颅外和颅内均对选择性RET抑制剂塞尔帕替尼有反应，凸显了LCNEC全面分子检测对选择最佳治疗方法的重要性。
